What factors drove the changes in Kyntra Bio's revenue and profit?

Did Kyntra Bio beat or miss consensus estimates last quarter?

What does Kyntra Bio do and what are its main business segments?

What is Kyntra Bio's latest dividend and current dividend yield?

What is Kyntra Bio's gross profit margin?

What were the key takeaways from Kyntra Bio’s earnings call?

What is the market's earnings forecast for Kyntra Bio next quarter?

What is the revenue and EPS growth rate for Kyntra Bio year over year?

- **Financial Restructuring Success**: 2025 net loss reduced 62% to $58.2M; cash runway extended to 2028 via $109.4M balance.
- **FG-3246 Milestone**: Phase II interim data due H2 2026; 10+ month rPFS target in post-ARPI setting.
- **Roxadustat Catalyst**: FDA Phase III feedback expected; $7M+ orphan exclusivity for MDS anemia.
- **Imaging Innovation**: FG-3180 PET agent could unlock $5B+ CD46-targeted ADC market.

**【CEO Summary Section】**
- **Transformational Year 2025**: Completed sale of FibroGen China to AstraZeneca, repaid senior secured term loan, and extended cash runway to 2028. Initiated Phase II trial for FG-3246/FG-3180 in mCRPC, with interim results expected H2 2026.
- **FG-3246 Program**: Targeting CD46, a tumor-selective epitope, with $5B+ U.S. market potential. Phase I monotherapy trial showed 8.7-month median rPFS; Phase II trial enrolling 75 patients in post-ARPI, pre-chemo setting. Companion PET agent FG-3180 demonstrated SUV correlation with PSA50 response in Phase Ib/II trial.
- **Roxadustat Update**: Received Orphan Drug Designation for MDS anemia. Phase III protocol submitted; FDA feedback expected in coming weeks, with trial initiation targeted for H2 2026.

**【CFO Financial Commentary】**
- **Revenue & Loss**: Q4 2025 revenue $1.3M vs. $3.1M YoY; full year $6.4M vs. $29.6M. Net loss from continuing ops: $58.2M (2025) vs. $153.1M (2024). 
- **Cash Position**: $109.4M as of Dec 31, 2025, with runway into 2028. R&D expenses reduced 75% YoY to $23.5M, reflecting cost optimization.

**【Q&A Highlights】**
- **Imaging & Commercialization**: FG-3180 PET agent could mirror PSMA PET agents' $2B 2025 revenue. Phase II trial evaluating SUV thresholds for patient selection; KOLs debate low vs. high SUV benefit.
- **Trial Design**: Phase II monotherapy trial enrolls healthier patients (1 prior ARPI) vs. Phase I (median 5 prior lines). G-CSF prophylaxis reduces neutropenia risk.
- **Roxadustat Strategy**: Exploring internal development or partnership for Phase III; FDA feedback expected soon.


Kyntra Bio, Inc. (KYNB) Q4 2025 Earnings Call Transcript

- **$220M China Sale**: Extended cash runway to 2028, reducing debt by $75M and receiving $6.4M of $10M holdback.
- **FG-3246 Milestones**: Phase II trial initiated with G-CSF prophylaxis; IST combo data due Q1 2026, interim Phase II results H2 2026.
- **Roxadustat Path**: FDA-aligned Phase III protocol for lower-risk MDS; $50-60M trial cost, exploring partner funding.
- **Financial Health**: Q3 2025 operating expenses down 86% YoY; $121.1M U.S. cash, no near-term liabilities beyond optional Phase III.

**【CEO Summary Section】**
- Completed sale of FibroGen China to AstraZeneca for $220M, extending cash runway to 2028 and paying off $75M term loan.
- Initiated Phase II monotherapy trial for FG-3246 in mCRPC with 75 patients, targeting optimal dose with G-CSF prophylaxis.
- Expected top-line results from FG-3246/enzalutamide IST in Q1 2026 and interim Phase II data in H2 2026.
- FDA-aligned Phase III protocol for roxadustat in lower-risk MDS with high transfusion burden, aiming for submission by end-2025.

**【CFO Financial Commentary】**
- Q3 2025 cash balance: $121.1M (U.S. only), with total operating costs reduced 86% YoY to $6.5M.
- Full-year 2025 operating expenses guidance: $50-60M, excluding potential Phase III trial costs ($50-60M).
- Received $6.4M of $10M holdback from China sale, with remaining $4M due Q2 2026.

**【Q&A Highlights】**
- Roxadustat Phase III cost: $50-60M, could reduce cash runway to mid-2027 if self-funded; exploring partnerships.
- FG-3246: 10.2-month rPFS in Ib IST combo trial; correlation between CD46/PSMA expression to be assessed in Phase II.
- No additional milestones for FG-3246 beyond $80M Phase III option; no royalty obligations post-approval.
- Decision on roxadustat trial path expected Q2 2026, with potential FDA-exclusivity supporting economic opportunity.

FibroGen, Inc. (FGEN) Q3 2025 Earnings Call Transcript

- **China Sale Boosts Liquidity**: $210 million transaction extends cash runway to 2028, enabling U.S. R&D focus.
- **FG-3246 Clinical Momentum**: Phase I rPFS of 8.7 months; Phase II trial with G-CSF prophylaxis to begin Q3.
- **Roxadustat Regulatory Clarity**: FDA-aligned Phase III design for MDS anemia; protocol submission Q4 2025.
- **Financial Efficiency**: 72% YoY expense reduction; cash flow positive despite $13.7 million net loss.

**【CEO Summary Section】**
- **FibroGen China Sale Update**: Total consideration increased to $210 million, extending cash runway into 2028. Transaction expected to close this quarter.
- **FG-3246 & FG-3180 Programs**: Phase I monotherapy trial showed 8.7-month rPFS in heavily pretreated mCRPC patients. Phase II trial to begin Q3 2025 with G-CSF prophylaxis; companion PET imaging agent (FG-3180) to assess CD46 expression.
- **Roxadustat Progress**: Positive Type-C FDA meeting; Phase III trial design agreed for anemia in lower-risk MDS. Protocol submission expected Q4 2025.

**【CFO Financial Commentary】**
- **Q2 2025 Financials**: Revenue $1.3 million (vs. $1 million in Q2 2024). Net loss $13.7 million, down 72% YoY. Operating expenses reduced 72% YoY to $13.4 million.
- **Cash Position**: $23.5 million in U.S., $142.1 million total. Cash flow positive Q2; expects to remain so until China sale close.
- **Debt Repayment**: Post-China sale, plans to pay off $80 million senior term loan, freeing up cash for U.S. programs.

**【Q&A Highlights】**
- **FG-3246 Phase III Design**: Control arm considerations include docetaxel; Phase II combo trial with enzalutamide to report Q4 2025 rPFS data.
- **Roxadustat Exclusivity**: 7-year Orphan Drug Designation; Phase III placebo-controlled trial with ~200 patients.
- **Clinical Focus**: FG-3246 Phase II targeting 10+ months rPFS; roxadustat trial to leverage MATTERHORN subgroup analysis.

FibroGen, Inc. (FGEN) Q2 2025 Earnings Call Transcript

- **China Deal Boost**: $185M sale extends cash runway to 2027H2, up from initial $160M guidance.
- **FG-3246 Momentum**: 8.7-month rPFS in Phase 1; FDA clears companion PET agent for Phase 2 trial (Q3 start).
- **Roxadustat Pathway**: FDA meeting Q3 to clarify MDS development path; post hoc data shows transfusion benefit.
- **Financial Resilience**: 76% YoY expense reduction; $33.8M U.S. cash + $128.4M total (incl. China).

**【CEO Strategic Update】**
- **China Divestiture**: Total consideration increased to $185M (from $160M), extending cash runway to H2 2027. Expected close in Q3 2025.
- **FG-3246 Progress**: Phase 1 monotherapy study shows 8.7-month rPFS in 40 heavily pretreated mCRPC patients. FDA cleared IND for companion PET imaging agent FG-3180, enabling Phase 2 dose optimization trial (Q3 start).
- **Roxadustat Update**: Filed Type C meeting request with FDA for lower-risk MDS indication. Post hoc analysis of MATTERHORN trial shows promise in reducing transfusion dependence.

**【CFO Financial Highlights】**
- **Q1 2025 Results**: Revenue $2.7M (down 90% YoY), operating expenses $17.7M (down 76% YoY). Net loss $16.8M vs. $49M YoY.
- **Cash Position**: $33.8M in U.S., $128.4M total (incl. China). Q1 cash flow positive ($7.3M). Post-China sale, plans to pay down $80M MSTV term loan.
- **2025 Guidance**: Operating expenses $70-80M (58% YoY reduction). Revenue $4-8M.

**【Q&A Key Takeaways】**
- **Clinical Design**: Phase 2 monotherapy trial will allow Pluvicto-experienced patients but not exclusively target them. FG-3180 will be used for all 75 patients to assess CD46 expression-response correlation.
- **FDA Engagement**: Positive interactions on IND approvals and Type C meeting scheduling. No macro regulatory headwinds noted.
- **Commercial Potential**: FG-3180 could become a $1.5B+ PET imaging agent if diagnostic performance validates. Colorectal cancer expansion on hold to prioritize mCRPC development.


FibroGen (FGEN)-12 May 25-2025 Q1 Earnings call transcript

- **$160M China Sale Transforms Cash Runway**: Closing by mid-2025 extends liquidity to 2027, enabling U.S. pipeline focus.
- **FG-3246 Shows Promise in mCRPC**: 8.7m RPFS in Phase I, with Phase II trial (75 pts) starting mid-2025.
- **Roxadustat MDS Opportunity**: FDA meeting Q2 2025 to discuss Phase III trial for ESA-refractory anemia.
- **Cost Cuts Drive Efficiency**: 51% YoY expense reduction to $180M, positioning for lean operations.
- **Key 2025 Milestones**: FG-3246 combo trial readout, Phase II interim analysis, and MDS regulatory clarity.


**【CEO Strategic Overview】**
- Sold FibroGen China to AstraZeneca for $160M, extending cash runway to 2027 and simplifying operations.
- Focused on U.S. pipeline: FG-3246 (ADC targeting CD46 in mCRPC) and FG-3180 (PET imaging companion).
- FG-3246 Phase I monotherapy trial showed 8.7 months RPFS in 40 heavily pretreated patients, with 20% ORR and 36% PSA >50% reduction.
- Planning Phase II monotherapy trial in post-ARSI, pre-chemo mCRPC patients (75 pts) with G-CSF prophylaxis to mitigate neutropenia.
- Exploring roxadustat for anemia in lower-risk MDS; FDA meeting Q2 2025 to discuss potential Phase III trial design.

**【CFO Financial Update】**
- Q4 2024 revenue: $3.1M (down 14% YoY), FY2024: $29.6M (down 37% YoY) due to China divestiture.
- Operating expenses reduced 51% YoY to $180M, driven by R&D ($95.7M, -64%) and SG&A ($49.3M, -43%).
- Net loss from continuing ops: $153.1M FY2024 vs $323M prior year.
- Cash as of Dec 31, 2024: $51M (US) + $121.1M (China), with $80M term loan payoff post-China sale closure.
- FY2025 guidance: Revenue $4-8M, OPEX $70-80M, cash runway to 2027 post-transaction.

**【Q&A Highlights】**
- FG-3246 Phase II futility analysis will assess safety and early efficacy at 12 pts per dose cohort; no details on thresholds.
- MDS trial likely 200 pts, leveraging roxadustat's safety database but requiring new data for MDS-specific endpoints.
- No plans to acquire new assets; focused on advancing existing pipeline.
- FDA feedback sought on roxadustat dosing (2.5mg/kg) and trial design for ESA-refractory MDS patients.
- FG-3246 Phase II combo trial with enzalutamide expects top-line data H2 2025, alongside CD46 biomarker correlation.

**【Risk Considerations】**
- Regulatory and clinical trial execution risks for FG-3246 and roxadustat.
- Dependence on China sale completion for liquidity improvement.
- Competitive dynamics in mCRPC (e.g., Pluvicto) and MDS anemia markets.
- Need for successful patient enrollment in Phase II trials to meet milestones.


Actual											-22.25	-23.75	8.75	-16	-19.5	-36.25	13.5	-36.25	-17	-19.5	-24.5	-17.5	-20.25	-22.5	-16.25	-14.25	-8.25	-4	-4.25	4.5	1.25	-1.88	49.61	-3.51
Forecast											-9.7132	-16.0046	-20.0008	-5.8488	-21.675	-12.05	-0.175	-16.5714	-20.7917	-23.0417	-20.25	-23.4583	-18.8333	-17.5971	-17.0269	-10.625	-10.4513	-8	-7.6575	-3.5	0.75	-2.3033	-4.007	-3.885
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-129.07%	-48.39%	+143.75%	-173.56%	+10.03%	-200.83%	+7814.29%	-118.75%	+18.24%	+15.37%	-20.99%	+25.40%	-7.52%	-27.86%	+4.56%	-34.12%	+21.06%	+50.00%	+44.50%	+228.57%	+66.67%	+18.38%	+1338.08%	+9.65%

Actual	--	--	--	--	--	--	--	--	--	--	24.40M	42.89M	44.03M	65.00M	38.43M	24.36M	155.97M	16.54M	60.83M	29.81M	15.73M	34.37M	36.16M	44.32M	40.13M	27.14M	55.90M	50.64M	46.33M	3.14M	2.70M	1.30M	1.08M	1.30M
Forecast	--	--	--	--	--	--	--	--	--	--	72.58M	48.29M	61.49M	100.81M	41.84M	69.08M	129.74M	47.65M	28.76M	36.16M	31.62M	23.97M	31.52M	34.73M	36.84M	38.90M	36.66M	34.66M	34.84M	24.90M	1.60M	2.63M	2.43M	1.67M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-66.38%	-11.18%	-28.39%	-35.52%	-8.15%	-64.73%	+20.22%	-65.28%	+111.51%	-17.57%	-50.24%	+43.38%	+14.71%	+27.62%	+8.94%	-30.24%	+52.47%	+46.10%	+32.98%	-87.41%	+68.75%	-50.56%	-55.80%	-22.16%

KYNB

KYNB fundamentals

KYNB Q4 2025 Earnings

Earnings Call

You can ask Aime

KYNB

KYNB fundamentals

KYNB Q4 2025 Earnings

Earnings Call

KYNB Earnings Call Summary for Q4/20255:00 PM on Mar 16, 2026

KYNB Earnings Call Summary for Q3/20255:00 PM on Nov 10, 2025

KYNB Earnings Call Summary for Q2/20255:00 PM on Aug 11, 2025

KYNB Earnings Call Summary for Q1/20255:00 PM on May 12, 2025

KYNB Earnings Call Summary for Q4/20245:00 PM on Mar 17, 2025

You can ask Aime